Tivic Health Systems, Inc. (NASDAQ:TIVC) Sees Significant Increase in Short Interest

Tivic Health Systems, Inc. (NASDAQ:TIVC) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totalling 100,200 shares, an increase of 47.6% from the August 15th total of 67,900 shares. Based on an average daily volume of 4,830,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.6% of the shares of the company are short sold.

Tivic Health Systems Stock Down 3.0 %

TIVC traded down $0.01 on Friday, reaching $0.29. The stock had a trading volume of 202,136 shares, compared to its average volume of 2,055,972. The business’s 50-day moving average price is $0.37 and its two-hundred day moving average price is $0.69. Tivic Health Systems has a 12-month low of $0.28 and a 12-month high of $3.21.

Tivic Health Systems (NASDAQ:TIVC) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.32) earnings per share (EPS) for the quarter. Tivic Health Systems had a negative net margin of 606.47% and a negative return on equity of 172.08%. The company had revenue of $0.14 million for the quarter.

Institutional Trading of Tivic Health Systems

An institutional investor recently bought a new position in Tivic Health Systems stock. Warberg Asset Management LLC purchased a new position in shares of Tivic Health Systems, Inc. (NASDAQ:TIVC) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 80,000 shares of the company’s stock, valued at approximately $31,000. Warberg Asset Management LLC owned 1.29% of Tivic Health Systems as of its most recent SEC filing. 4.25% of the stock is currently owned by institutional investors.

About Tivic Health Systems

Tivic Health Systems Inc operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S.